Lactate serum concentrations during treatment with nucleos(t)ide analogues in hepatitis B with or without cirrhosis
| Autor: | Konstantinos Thomopoulos, Georgia Vourli, Giorgos Tsiaoussis, Charalambos Gogos, Dimitra Taprantzi, Christos Triantos, Martha Mandellou, Maria Kalafateli, Ioanna Aggeletopoulou, Evangelos D. Anastassiou, Paraskevi Tselekouni, Stelios F Assimakopoulos, Chrisoula Labropoulou-Karatza |
|---|---|
| Rok vydání: | 2017 |
| Předmět: |
Adult
Liver Cirrhosis Male medicine.medical_specialty Guanine Time Factors Cirrhosis Organophosphonates Antiviral Agents Gastroenterology Young Adult 03 medical and health sciences Hepatitis B Chronic Sex Factors 0302 clinical medicine Risk Factors Internal medicine medicine Humans Lactic Acid Prospective Studies 030212 general & internal medicine Tenofovir Prospective cohort study Aged Acidosis Aged 80 and over Hepatology business.industry Adenine Lamivudine Entecavir Middle Aged Hepatitis B medicine.disease Up-Regulation Treatment Outcome Hepatocellular carcinoma Lactic acidosis Acidosis Lactic Drug Therapy Combination Female 030211 gastroenterology & hepatology medicine.symptom business Biomarkers medicine.drug |
| Zdroj: | European Journal of Gastroenterology & Hepatology. 29:998-1003 |
| ISSN: | 0954-691X |
| DOI: | 10.1097/meg.0000000000000924 |
| Popis: | Objective The aim of this study is to evaluate the clinical implications of lactate concentrations in patients with hepatitis B with or without cirrhosis during treatment with nucleos(t)ide analogues. Patients and methods One hundred and seven consecutive patients with chronic hepatitis B and median age 57 (24-85) years were prospectively included. Lactate concentrations were measured at baseline and at 12, 24, 36, 48, and 60 months following the baseline measurements. Eight (n=8, 7.5%) patients received lamivudine, 38 (n=38, 35.5%) patients received tenofovir, 34 (n=34, 31.8%) patients received entecavir, and 27 (n=27, 25.2%) patients received combined therapy. Results None of the patients developed lactic acidosis during follow-up [median: 58 (6-155) months]. Overall, no trends of the lactic acid evolution were observed over time; however, there was a nonsignificant increasing trend in patients with cirrhosis up to 24 months of treatment. This increasing trend was significant in female patients with cirrhosis (P=0.016). The age of the patients, the presence of cirrhosis, and hepatocellular carcinoma were strongly associated with the survival of all patients. In the group of cirrhotic patients, the only independent prognostic factor that was associated with patients' survival was the Child-Pugh class. Conclusion None of the patients developed lactic acidosis. There is an indication of an increasing trend of lactic acid levels up to 24 months of therapy in female cirrhotic patients. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|